The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection
Beddingfield, Brandon J.
Chapagain, Prem P.
Roy, Chad J.
Hu, Tony Y.
Kolls, Jay K.
Bix, Gregory J.
MetadataShow full item record
Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized α5β1 integrin-based mechanism, and indicates that inhibiting the spike protein interaction with α5β1 integrin (+/- ACE2), and the interaction between α5β1 integrin and ACE2 using a novel molecule ATN-161 represents a promising approach to treat COVID-19.
Link to resourcehttps://doi.org/10.1016/j.jacbts.2020.10.003
Estadísticas Google Analytics
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.